- Home
- BCAT vs NVCR Comparison
BCAT vs NVCR Comparison
Compare BCAT & NVCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BCAT | NVCR |
|---|---|---|
| Founded | 2020 | 2000 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | BCAT | NVCR |
|---|---|---|
| Price | $14.51 | $12.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $28.42 |
| AVG Volume (30 Days) | 308.8K | ★ 1.8M |
| Earning Date | 01-01-0001 | 10-30-2025 |
| Dividend Yield | ★ 9.38% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.43 | N/A |
| Revenue | N/A | ★ $642,269,000.00 |
| Revenue This Year | N/A | $9.75 |
| Revenue Next Year | N/A | $5.62 |
| P/E Ratio | $11.41 | ★ N/A |
| Revenue Growth | N/A | ★ 11.17 |
| 52 Week Low | $13.67 | $10.70 |
| 52 Week High | $16.38 | $34.13 |
Technical Indicators
Market Signals| Indicator | BCAT | NVCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.53 | 49.48 |
| Support Level | $13.73 | $10.79 |
| Resistance Level | $14.57 | $11.86 |
| Average True Range (ATR) | 0.15 | 0.60 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 92.86 | 60.48 |
Price Performance
Historical ComparisonAbout BCAT BlackRock Capital Allocation Term Trust of Beneficial Interest
BlackRock Capital Allocation Trust is a non-diversified, closed-end management investment company. The investment objective is to provide total return and income through a combination of current income, current gains and long-term capital appreciation.
About NVCR NovoCure Limited
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.